|
1
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al: TARGET Study Group: Sorafenib in advanced clear-cell
renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Motzer RJ, Rini BI, Bukowski RM, Curti BD,
George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G,
et al: Sunitinib in patients with metastatic renal cell carcinoma.
JAMA. 295:2516–2524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Motzer RJ, Escudier B, Oudard S, Hutson
TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA,
Hollaender N, et al: RECORD-1 Study Group: Phase 3 trial of
everolimus for metastatic renal cell carcinoma: Final results and
analysis of prognostic factors. Cancer. 116:4256–4265. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu Y and Ye Y: Proteostasis regulation at
the endoplasmic reticulum: A new perturbation site for targeted
cancer therapy. Cell Res. 21:867–883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bali P, Pranpat M, Bradner J, Balasis M,
Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, et
al: Inhibition of histone deacetylase 6 acetylates and disrupts the
chaperone function of heat shock protein 90: A novel basis for
antileukemia activity of histone deacetylase inhibitors. J Biol
Chem. 280:26729–26734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Naujokat C and Hoffmann S: Role and
function of the 26S proteasome in proliferation and apoptosis. Lab
Invest. 82:965–980. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sato A and Asano T, Ito K, Sumitomo M and
Asano T: Suberoylanilide hydroxamic acid (SAHA) combined with
bortezomib inhibits renal cancer growth by enhancing histone
acetylation and protein ubiquitination synergistically. BJU Int.
109:1258–1268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sato A and Asano T, Isono M, Ito K and
Asano T: Panobinostat synergizes with bortezomib to induce
endoplasmic reticulum stress and ubiquitinated protein accumulation
in renal cancer cells. BMC Urol. 14:712014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yeo W, Chung HC, Chan SL, Wang LZ, Lim R,
Picus J, Boyer M, Mo FK, Koh J, Rha SY, et al: Epigenetic therapy
using belinostat for patients with unresectable hepatocellular
carcinoma: A multicenter phase I/II study with biomarker and
pharmacokinetic analysis of tumors from patients in the Mayo Phase
II Consortium and the Cancer Therapeutics Research Group. J Clin
Oncol. 30:3361–3367. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mackay HJ, Hirte H, Colgan T, Covens A,
MacAlpine K, Grenci P, Wang L, Mason J, Pham PA, Tsao MS, et al:
Phase II trial of the histone deacetylase inhibitor belinostat in
women with platinum resistant epithelial ovarian cancer and
micropapillary (LMP) ovarian tumours. Eur J Cancer. 46:1573–1579.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ramalingam SS, Belani CP, Ruel C, Frankel
P, Gitlitz B, Koczywas M, Espinoza-Delgado I and Gandara D: Phase
II study of belinostat (PXD101), a histone deacetylase inhibitor,
for second line therapy of advanced malignant pleural mesothelioma.
J Thorac Oncol. 4:97–101. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Giaccone G, Rajan A, Berman A, Kelly RJ,
Szabo E, Lopez-Chavez A, Trepel J, Lee MJ, Cao L, Espinoza-Delgado
I, et al: Phase II study of belinostat in patients with recurrent
or refractory advanced thymic epithelial tumors. J Clin Oncol.
29:2052–2059. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cashen A, Juckett M, Jumonville A, Litzow
M, Flynn PJ, Eckardt J, LaPlant B, Laumann K, Erlichman C and
DiPersio J: Phase II study of the histone deacetylase inhibitor
belinostat (PXD101) for the treatment of myelodysplastic syndrome
(MDS). Ann Hematol. 91:33–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gimsing P, Hansen M, Knudsen LM, Knoblauch
P, Christensen IJ, Ooi CE and Buhl-Jensen P: A phase I clinical
trial of the histone deacetylase inhibitor belinostat in patients
with advanced hematological neoplasia. Eur J Haematol. 81:170–176.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paoluzzi L, Scotto L, Marchi E, Zain J,
Seshan VE and O'Connor OA: Romidepsin and belinostat synergize the
antineoplastic effect of bortezomib in mantle cell lymphoma. Clin
Cancer Res. 16:554–565. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Spratlin JL, Pitts TM, Kulikowski GN,
Morelli MP, Tentler JJ, Serkova NJ and Eckhardt SG: Synergistic
activity of histone deacetylase and proteasome inhibition against
pancreatic and hepatocellular cancer cell lines. Anticancer Res.
31:1093–1103. 2011.PubMed/NCBI
|
|
17
|
Dai Y, Chen S, Wang L, Pei XY, Kramer LB,
Dent P and Grant S: Bortezomib interacts synergistically with
belinostat in human acute myeloid leukaemia and acute lymphoblastic
leukaemia cells in association with perturbations in NF-κB and Bim.
Br J Haematol. 153:222–235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Feng R, Oton A, Mapara MY, Anderson G,
Belani C and Lentzsch S: The histone deacetylase inhibitor, PXD101,
potentiates bortezomib-induced anti-multiple myeloma effect by
induction of oxidative stress and DNA damage. Br J Haematol.
139:385–397. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lemoine M and Younes A: Histone
deacetylase inhibitors in the treatment of lymphoma. Discov Med.
10:462–470. 2010.PubMed/NCBI
|
|
20
|
Vindeløv LL, Christensen IJ and Nissen NI:
A detergent-trypsin method for the preparation of nuclei for flow
cytometric DNA analysis. Cytometry. 3:323–327. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kanayama H, Tanaka K, Aki M, Kagawa S,
Miyaji H, Satoh M, Okada F, Sato S, Shimbara N and Ichihara A:
Changes in expressions of proteasome and ubiquitin genes in human
renal cancer cells. Cancer Res. 51:6677–6685. 1991.PubMed/NCBI
|
|
22
|
Liu CY, Takemasa A, Liles WC, Goodman RB,
Jonas M, Rosen H, Chi E, Winn RK, Harlan JM and Chuang PI:
Broad-spectrum caspase inhibition paradoxically augments cell death
in TNF-alpha-stimulated neutrophils. Blood. 101:295–304. 2003.
View Article : Google Scholar : PubMed/NCBI
|
